Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Notes Payables (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Notes Payables readings, the most recent being $60898.0 for Q1 2025.

  • Quarterly Notes Payables changed N/A to $60898.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $60898.0 through Mar 2025, changed N/A year-over-year, with the annual reading at $662324.0 for FY2024, N/A changed from the prior year.
  • Notes Payables hit $60898.0 in Q1 2025 for Drugs Made In America Acquisition, down from $662324.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $662324.0 in Q4 2024 and bottomed at $60898.0 in Q1 2025.